Anthem Biosciences Ltd
ANTHEM • Health Care
ROCE
33.50%
FY24 Actual
D/E Ratio
0.05
Zero Debt
5Y Rev CAGR
14.9%
High Growth
Profit Margin
| Metrics (Values in Cr) | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | TTM |
|---|---|---|---|---|---|---|
| Total Revenue | 1,280.24 | 1,195.79(-6.6%) |
ANTHEM • Health Care
ROCE
33.50%
FY24 Actual
D/E Ratio
0.05
Zero Debt
5Y Rev CAGR
14.9%
High Growth
Profit Margin
| Metrics (Values in Cr) | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | TTM |
|---|---|---|---|---|---|---|
| Total Revenue | 1,280.24 | 1,195.79(-6.6%) |
27.6%
5Y Average
1,930.28(+30.2%) |
2,280.12(+18.1%) |
2,281.1 |
| Operating Revenue | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — |
| Operating Profit | — | — | — | — | — | — |
| Raw Profit | 410.3 | 348.29(-15.1%) | 640.79(+84.0%) | 830.62(+29.6%) | — | — |
| Operating Expenses | 33.82 | 24.75(-26.8%) | 3.23(-86.9%) | -29.89(-1025.4%) | 1,314.91(-4499.2%) | 1,315.89 |
| Selling General And Administrative Expenses | 48.3 | 60.79(+25.9%) | 55.19(-9.2%) | 64.52(+16.9%) | — | — |
| Depreciation And Amortization | 57.76 | 63.7(+10.3%) | 81.82(+28.4%) | 89.37(+9.2%) | 134.07(+50.0%) | 134.07 |
| Profit Before Interest | 556.22 | 506.01(-9.0%) | 486.98(-3.8%) | 667.39(+37.0%) | 831.14(+24.5%) | 831.14 |
| Interest Expense | 10.09 | 8.72(-13.6%) | 9.66(+10.8%) | 10.53(+9.0%) | 6.89(-34.6%) | 6.89 |
| Profit Before Tax | 546.13 | 497.29(-8.9%) | 477.32(-4.0%) | 656.86(+37.6%) | 824.25(+25.5%) | 824.25 |
| Tax Expense | 140.6 | 112.11(-20.3%) | 110.01(-1.9%) | 205.61(+86.9%) | 232.45(+13.1%) | 232.45 |
| Net Income | 405.53 | 385.18(-5.0%) | 367.31(-4.6%) | 451.25(+22.9%) | 591.8(+31.1%) | 591.8 |
| Earnings Per Share | 7.229 | 6.752(-6.6%) | 6.504(-3.7%) | 8.071(+24.1%) | 10.55(+30.7%) | 10.585 |
| Dividends Per Share | 0 | 0 | 0 | 0 | 0 | 0 |
| Payout Ratio | 0 | 0 | 0 | 0 | 0 | 0 |